Cargando…
Bendamustine in patients with relapsed or refractory multiple myeloma
OBJECTIVE: In patients with multiple myeloma, bendamustine monotherapy is effective as 1(st )and 2(nd )line therapy. However, data for patients with advanced multiple myeloma is rare. METHODS: In this retrospective analysis we have identified 39 patients with relapsed or refractory multiple myeloma...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3351842/ https://www.ncbi.nlm.nih.gov/pubmed/20159666 http://dx.doi.org/10.1186/2047-783X-15-1-13 |
_version_ | 1782232806668107776 |
---|---|
author | Michael, M Bruns, I Bölke, E Zohren, F Czibere, A Safaian, N N Neumann, F Haas, R Kobbe, G Fenk, R |
author_facet | Michael, M Bruns, I Bölke, E Zohren, F Czibere, A Safaian, N N Neumann, F Haas, R Kobbe, G Fenk, R |
author_sort | Michael, M |
collection | PubMed |
description | OBJECTIVE: In patients with multiple myeloma, bendamustine monotherapy is effective as 1(st )and 2(nd )line therapy. However, data for patients with advanced multiple myeloma is rare. METHODS: In this retrospective analysis we have identified 39 patients with relapsed or refractory multiple myeloma by means of case research, who have been treated at our institution with bendamustine as salvage therapy. After in median 2 lines of prior therapy (range:1-5) patients received in median 3 (range: 1-10) cycles of bendamustine. Bendamustine dosage was 80-150 mg on day 1+2 of a monthly cycle. Bendamustine was administered as monotherapy in 39% of patients, whereas 61% received concomitant steroids. RESULTS: Toxicity was mild to moderate. Response rates were as follows: 3% vgPR, 33% PR, 18% MR, 26% SD and 20% PD. The median event-free and overall survival were 7 and 17 months, respectively. CONCLUSIONS: In conclusion, in patients with advanced multiple myeloma bendamustine is effective and associated with mild toxicity. Therefore, the role of bendamustine in patients with multiple myeloma should be investigated in further clinical trials. |
format | Online Article Text |
id | pubmed-3351842 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-33518422012-05-16 Bendamustine in patients with relapsed or refractory multiple myeloma Michael, M Bruns, I Bölke, E Zohren, F Czibere, A Safaian, N N Neumann, F Haas, R Kobbe, G Fenk, R Eur J Med Res Research OBJECTIVE: In patients with multiple myeloma, bendamustine monotherapy is effective as 1(st )and 2(nd )line therapy. However, data for patients with advanced multiple myeloma is rare. METHODS: In this retrospective analysis we have identified 39 patients with relapsed or refractory multiple myeloma by means of case research, who have been treated at our institution with bendamustine as salvage therapy. After in median 2 lines of prior therapy (range:1-5) patients received in median 3 (range: 1-10) cycles of bendamustine. Bendamustine dosage was 80-150 mg on day 1+2 of a monthly cycle. Bendamustine was administered as monotherapy in 39% of patients, whereas 61% received concomitant steroids. RESULTS: Toxicity was mild to moderate. Response rates were as follows: 3% vgPR, 33% PR, 18% MR, 26% SD and 20% PD. The median event-free and overall survival were 7 and 17 months, respectively. CONCLUSIONS: In conclusion, in patients with advanced multiple myeloma bendamustine is effective and associated with mild toxicity. Therefore, the role of bendamustine in patients with multiple myeloma should be investigated in further clinical trials. BioMed Central 2010-01-29 /pmc/articles/PMC3351842/ /pubmed/20159666 http://dx.doi.org/10.1186/2047-783X-15-1-13 Text en Copyright ©2010 I. Holzapfel Publishers |
spellingShingle | Research Michael, M Bruns, I Bölke, E Zohren, F Czibere, A Safaian, N N Neumann, F Haas, R Kobbe, G Fenk, R Bendamustine in patients with relapsed or refractory multiple myeloma |
title | Bendamustine in patients with relapsed or refractory multiple myeloma |
title_full | Bendamustine in patients with relapsed or refractory multiple myeloma |
title_fullStr | Bendamustine in patients with relapsed or refractory multiple myeloma |
title_full_unstemmed | Bendamustine in patients with relapsed or refractory multiple myeloma |
title_short | Bendamustine in patients with relapsed or refractory multiple myeloma |
title_sort | bendamustine in patients with relapsed or refractory multiple myeloma |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3351842/ https://www.ncbi.nlm.nih.gov/pubmed/20159666 http://dx.doi.org/10.1186/2047-783X-15-1-13 |
work_keys_str_mv | AT michaelm bendamustineinpatientswithrelapsedorrefractorymultiplemyeloma AT brunsi bendamustineinpatientswithrelapsedorrefractorymultiplemyeloma AT bolkee bendamustineinpatientswithrelapsedorrefractorymultiplemyeloma AT zohrenf bendamustineinpatientswithrelapsedorrefractorymultiplemyeloma AT cziberea bendamustineinpatientswithrelapsedorrefractorymultiplemyeloma AT safaiannn bendamustineinpatientswithrelapsedorrefractorymultiplemyeloma AT neumannf bendamustineinpatientswithrelapsedorrefractorymultiplemyeloma AT haasr bendamustineinpatientswithrelapsedorrefractorymultiplemyeloma AT kobbeg bendamustineinpatientswithrelapsedorrefractorymultiplemyeloma AT fenkr bendamustineinpatientswithrelapsedorrefractorymultiplemyeloma |